1. What Happened?

Golden Core No. 1 sold 476,190 shares of Adbiotech on August 12, 2025, through an off-market transaction. This reduced their stake from 8.87% to 4.45%.

2. Why the Sale?

While Golden Core No. 1 stated the reason as a change in ‘simple investment’ objectives, the specific reason remains unclear. Speculations range from profit-taking to a shift in investment strategy, creating uncertainty and concern among investors.

3. What Does This Mean for the Stock Price?

The large sell-off could exert downward pressure on the stock price in the short term, potentially leading to a supply-demand imbalance and dampened investor sentiment. However, Adbiotech’s Q1 sales growth and efforts to improve its financial structure could be positive factors. The growth potential of the next-generation antibody-based animal pharmaceuticals market is also noteworthy.

  • Direct Impact: Downward pressure on stock price, supply-demand imbalance.
  • Indirect Impact: Weakened investor sentiment.

4. What Should Investors Do?

  • Short-Term Strategy: Wait and see, seek additional information.
  • Long-Term Strategy: Continuous fundamental analysis, monitor profitability improvements.

In the short term, it’s advisable to wait and see how the market digests the news of the share sale. Investors should closely monitor any further disclosures from Adbiotech’s management or Golden Core No. 1. For the long term, continuous monitoring of the company’s fundamentals – core technology, pipeline development, and new business performance – is crucial. Pay close attention to whether Adbiotech achieves profitability and strengthens its financial health.